All Stories

Arbutus regains China rights to potential functional hep B cure as part of strategic rethink

Arbutus had made no secret of its desire to step up its plans for imdusiran. Now, the company has regained the China rights to the potential functional cure for hepatitis B.

Jun 25, 2025 - 15:05
 0
Arbutus regains China rights to potential functional hep B cure as part of strategic rethink
Arbutus had made no secret of its desire to step up its plans for imdusiran. Now, the company has regained the China rights to the potential functional cure for hepatitis B.
Read More

Tags:

Previous Article

Kymera suffers Sanofi setback but secures $750M Gilead deal

Next Article

Bayer-owned BlueRock lays off 50 employees, shutters Cambridge research labs

Related Posts

ASCO: Kite's CAR-T passes lymphoma safety trial with flying colors

ASCO: Kite's CAR-T passes lymphoma safety trial with fl...

Jun 1, 2025  0

HHS axes Moderna's $590M pandemic bird flu vaccine contract, ending funding for late-phase trials

HHS axes Moderna's $590M pandemic bird flu vaccine cont...

May 29, 2025  0

ASCO: Uneven US clinical trial spread leaves millions of women without access to breast cancer studies

ASCO: Uneven US clinical trial spread leaves millions o...

Jun 2, 2025  0